Drug Profile
Memantine - Children's Medical Center Corporation/Merz Pharma
Alternative Names: Akatinol; Axura; D-145; Ebixa; Extended-release memantine capsules - AbbVie; Memantine hydrochloride; Memary; Namenda; Namenda XR; SUN Y7017; SUNY 017Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Childrens Medical Center Corporation
- Developer AbbVie; Allergan; Daiichi Sankyo Company; Forest Laboratories; Lundbeck A/S; Merz Pharma; Neurobiological Technologies; University of California, Davis
- Class Amines; Analgesics; Antidementias; Antiglaucomas; Antiparkinsonians; Antispastics; Antitussives; Eye disorder therapies; Nitrates; Nootropics; Organic bridged compounds; Small molecules; Vascular disorder therapies
- Mechanism of Action Nicotinic receptor antagonists; NMDA receptor antagonists; Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Alzheimer's disease; Cognition disorders; Dementia
- Phase III Vascular dementia
- Discontinued Asperger syndrome; Autistic disorder; Diabetic neuropathies; Fragile X tremor ataxia syndrome; Glaucoma; Neuropathic pain
Most Recent Events
- 01 Jun 2022 Merz Pharmaceuticals completes its phase III clinical trials in Vascular dementia in Russia (PO) (NCT03986424)
- 26 Apr 2022 Phase III development for Vascular dementia is still ongoing in Russia (PO) (NDR batch 22)
- 22 Apr 2022 Merz Pharma completes enrolment in a phase III clinical trials in Vascular dementia in Russia (PO) (NCT03986424)